[특허]Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols

Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols 원문보기

IPC분류정보
국가/구분	United States(US) Patent 등록
국제특허분류(IPC7판)	A61K-031/355 A61K-031/352
출원번호	US-0020450 (2001-12-14)
발명자 / 주소	Miller,Guy Brown,Lesley A. Del Balzo,Ughetta Flaim,Stephen Boddupalli,Sekhar Wang,Bing
출원인 / 주소	Galileo Pharmaceuticals, Inc.
인용정보	피인용 횟수 : 29 인용 특허 : 35

초록

The present invention provides method for the treatment of a symptom of neuronal damage associated with cerebral ischemia comprising administering gamma-, beta-, or delta-tocopherol enriched tocopherol compositions.

대표청구항 ▼

We claim: 1. A method for treating and/or ameliorating a symptom of neuronal damage associated with a cerebral ischemic condition in a mammalian subject, comprising administering to the subject an effective amount of a non-alpha tocopherol enriched tocopherol composition, and by said administering, reducing neuronal damage related to said cerebral ischemic condition. 2. The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a gamma-tocopherol enriched tocopherol composition. 3. The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a beta-tocopherol enriched tocopherol composition. 4. The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a delta-tocopherol enriched tocopherol composition. 5. The method of claim 1 wherein the cerebral ischemic condition is secondary to an occlusion of the cerebral vasculature. 6. The method of claim 5 wherein the occlusion is due to a thromboembolus. 7. The method of claim 1 wherein the cerebral ischemia is due to a spasm of the coronary vasculature. 8. The method of claim 1 wherein the cerebral ischemic condition is secondary to a cessation of cardiac function. 9. The method of claim 1 wherein the cerebral ischemic condition is secondary to a cardiopulmonary bypass procedure. 10. The method of claim 1 wherein the cerebral ischemic condition is secondary to a hemorrhagic event in the cerebral vasculature. 11. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 60% gamma-tocopherol. 12. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 65% gamma-tocopherol. 13. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 70% ma-tocopherol. 14. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 75% gamma-tocopherol. 15. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 80% gamma-tocopherol. 16. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 85% gamma-tocopherol. 17. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 90% gamma-tocopherol. 18. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 95% gamma-tocopherol. 19. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 98% gamma-tocopherol. 20. The method of claim 3 herein said beta-tocopherol enriched tocopherol composition comprises at least 50% beta-tocopherol. 21. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 65% be-tocopherol. 22. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 75% beta-tocopherol. 23. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 90% beta-tocopherol. 24. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 95% beta-tocopherol. 25. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 98% beta-tocopherol. 26. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 50% delta-tocopherol. 27. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 65% delta-tocopherol. 28. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 75% delta-tocopherol. 29. The method of claim wherein said delta-tocopherol enriched tocopherol composition comprises at least 90%/o delta-tocopherol. 30. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 95% delta-tocopherol. 31. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 98% delta-tocopherol. 32. The method of claim 1 wherein said composition is a nutritional composition. 33. The method of claim 1 wherein said composition is a pharmaceutical composition. 34. The method of claim 1 wherein said composition is administered orally. 35. The method of claim 1 wherein said composition is administered parenterally. 36. The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 1-1000 mg per kg body weight of said mammalian subject. 37. The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 1-50 mg per kg body weight of said mammalian subject. 38. The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 10-100 mg per kg body weight of said mammalian subject. 39. The method of claim 1, wherein said neuronal damage is neuronal cell death. 40. The method of claim 1, wherein said neuronal damage is total cerebral infarct volume. 41. The method of claim 1, wherein said neuronal damage is total cerebral ischemic damage. 42. The method of claim 1, wherein said neuronal damage is cerebral tissue edema. 43. The method of claim 1, wherein said neuronal damage is cognitive dysfunction.

이 특허에 인용된 특허 (35)

Bednar Martin M. ; Gross Cordell E. ; Thomas G. Roger, Anti-CD18 antibodies in stroke.
상세보기
Chabrier de Lassauniere Pierre-Etienne,FRX ; Bigg Dennis,FRX, Association of no syntase inhibitors with trappers of oxygen reactive forms.
상세보기
Wingard Robert E. (Palo Alto CA), Conversion of hesperidin into hesperetin.
상세보기
Kenneth L. Hensley ; Robert A. Floyd, Desmethyl tocopherols for protecting cardiovascular tissue.
상세보기
Venero Aurelio O. (Paseo del Puerto 24 48990 Neguri ESX) Pestana Ramon M. (Avenida Iparraguirre ; 20 ; 7°A 48940 Lejona ESX), Diosmin octakis (hydrogen sulfate) aluminum complex.
상세보기
Cassels Bruce Kennedy,CLX ; Dajas Federico Jose,UYX ; Medina Jorge Horacio,ARX ; Paladini Alejandro Constantino,ARX ; Silveira Rodolfo Horacio,UYX, Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity.
상세보기
Becker Kyra J. ; Hallenbeck John M. ; McCarron Richard M., Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof.
상세보기
Gorbach Sherwood L., Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions.
상세보기
Miller Guy ; Lou Lillian ; Nakamura John, Method and composition for inhibiting cellular irreversible changes due to stress.
상세보기
Potter Susan M. ; Henley Edna C. ; Waggle Doyle H., Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce.
상세보기
Clarkson ; Jr. Thomas Boston ; Anthony Mary Susan ; Pan Yuanlong ; Adams Michael R. ; Waggle Doyle H., Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive functio.
상세보기
Koudsi Basem (St. Louis MO) Wun Tze-Chein (St. Louis MO), Method of inhibiting tissue ischemia and reperfusion injury.
상세보기
Fukuda Hidenori (Odawara JPX), Multiple emulsion having a form of water/oil/water phase and process for preparation thereof, and multiple emulsion type.
상세보기
Wechter William J. ; Murray David E. ; Kantoci Darko ; Levine Barry H. ; Benaksas Elaine J., Natriuretic compounds.
상세보기
Wechter William J. ; Murray David E. ; Kantoci Darko ; Levine Barry H. ; Benaksas Elaine J., Natriuretic compounds.
상세보기
Marangos Paul J. ; Sullivan Brian W. ; Wiemann Torsten ; Danks Anne M. ; Sragovicz Marina ; Makings Lewis R., Neuroprotective poly-guanidino compounds which block presynaptic N and P/Q calcium channels.
상세보기
Orjales-Venero Aurelio (Neguri ESX) Mosquera-Pestana Ramon (Las Arenas ESX), New sulfated diosmin derivative.
상세보기
Figueroa ; Jr. Ramon (Oxford CT) Harrison ; Jr. Bobby G. (East Norwalk CT) SaNogueira James P. (Newtown CT), Oil-in-water-in-silicone emulsion compositions.
상세보기
Kim Young D. (Seoul KRX) Ha Byung J. (Seoul KRX), Polyethoxylated vitamin E.
상세보기
Kuo Yeong J. (Kingsport TN) Hartley Gary W. (Kingsport TN) Gustafson Bruce L. (Kingsport TN) Allen David J. (Kingsport TN), Preparation of a 상세보기

내보내기 메뉴

내보내기 구분

파일저장
인쇄
메일전송

구성항목

기본정보
상세정보

관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC

저장형식

Text(ASCII format)
Excel format
PIAS분석(.xls)

메일정보

받는사람 (필수): @
보내는사람 (선택): @
제목
내용: KISTI 검색결과 이메일 서비스

안내

총 건의 자료가 검색되었습니다.

다운받으실 자료의 인덱스를 입력하세요. (1-10,000)

검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다.

데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요)

다운로드 파일은 UTF-8 형태로 저장됩니다.
파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오.

Text(ASCII format)
Excel format

AI-Helper ※ AI-Helper는 을 사용합니다.

AI-Helper

안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

IPC	Description
A	생활필수품
A62	인명구조; 소방(사다리 E06C)
A62B	인명구조용의 기구, 장치 또는 방법(특히 의료용에 사용되는 밸브 A61M 39/00; 특히 물에서 쓰이는 인명구조 장치 또는 방법 B63C 9/00; 잠수장비 B63C 11/00; 특히 항공기에 쓰는 것, 예. 낙하산, 투출좌석 B64D; 특히 광산에서 쓰이는 구조장치 E21F 11/00)
A62B-1/08	.. 윈치 또는 풀리에 제동기구가 있는 것

연합인증

Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols 원문보기

초록

대표청구항 ▼

연구과제 타임라인

이 특허에 인용된 특허 (35)

이 특허를 인용한 특허 (29)

관련 콘텐츠

특허 원문 보기

IPC 상위 출원인

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 공고번호, 공고일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표출원인, 출원인국적, 출원인주소, 발명자, 발명자E, 발명자코드, 발명자주소, 발명자 우편번호, 발명자국적, 대표IPC, IPC코드, 요약, 미국특허분류, 대리인주소, 대리인코드, 대리인(한글), 대리인(영문), 국제공개일자, 국제공개번호, 국제출원일자, 국제출원번호, 우선권, 우선권주장일, 우선권국가, 우선권출원번호, 원출원일자, 원출원번호, 지정국, Citing Patents, Cited Patents
저장형식	Text(ASCII format) Excel format PIAS분석(.xls)
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols 원문보기

초록

대표청구항 ▼

연구과제 타임라인

전체(0) 논문(0) 특허(0) 보고서(0)

전체(0) 논문(0) 특허(0) 보고서(0)

이 특허에 인용된 특허 (35)

이 특허를 인용한 특허 (29)

관련 콘텐츠

특허 원문 보기

IPC 상위 출원인

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트